ADMA Biologics COO has shares withheld for taxes

ADMA Biologics executive Kaitlin M. Kestenberg-Messina, COO and SVP, Compliance, reported a tax-withholding disposition of 3,177 shares of common stock at $8.37 per share to satisfy mandatory taxes on vested RSUs.

Rhea-AI Filing Summary

ADMA Biologics executive Kaitlin M. Kestenberg-Messina, COO and SVP, Compliance, reported a tax-withholding disposition of 3,177 shares of common stock at $8.37 per share to satisfy mandatory taxes on vested RSUs. This was not an open-market sale. After the transaction she directly owned 443,061 shares, in addition to multiple unvested RSU grants that will settle into common stock as they vest.

Insider Trade Summary

Tax Withholding: 3,177 shares

Tax Withholding 1 txn

Insider Kestenberg-Messina Kaitlin M.

Role COO and SVP, Compliance

Type	Security	Shares	Price	Value
Tax Withholding	Common Stock F1, F2, F3	3,177	$8.37	$27K

Holdings After Transaction: Common Stock — 443,061 shares (Direct)

Footnotes (3)

1. F1. Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon the non-reportable vesting and settlement of restricted stock units ("RSUs"). This is not an open market sale of securities.
2. F2. Includes, as of the transaction date, (i) 91,631 unvested RSUs out of 91,631 RSUs granted on February 9, 2026, vesting 25% on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (ii) 58,338 unvested RSUs out of 77,784 RSUs granted on February 19, 2025, vesting 25% on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (iii) 96,160 unvested RSUs out of 192,320 RSUs granted on April 1, 2024, vesting 25% on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;
3. F3. (continued from footnote 2) (iv) 7,500 unvested RSUs out of 30,000 RSUs granted on July 24, 2023, vesting 25% on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (v) 23,750 unvested RSUs out of 95,000 RSUs granted on March 6, 2023, vesting 25% on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; and (vi) 165,682 shares of common stock directly owned by the Reporting Person, which reflects prior option exercises and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes. Each RSU represents a contingent right to receive one share of common stock of the Issuer.

Key Figures

Shares withheld for taxes: 3,177 shares Per-share value for withholding: $8.37 per share Direct holdings after transaction: 443,061 shares +3 more

6 metrics

Shares withheld for taxes 3,177 shares Code F tax-withholding disposition of common stock

Per-share value for withholding $8.37 per share Value used for tax-withholding on 3,177 common shares

Direct holdings after transaction 443,061 shares Common shares directly owned following the tax-withholding event

Unvested RSUs from Feb. 9, 2026 grant 91,631 RSUs Unvested RSUs from a 91,631-unit grant vesting 25% annually over four years

Unvested RSUs from Apr. 1, 2024 grant 96,160 RSUs Unvested portion of a 192,320-unit RSU grant vesting annually over four years

Previously accumulated common shares 165,682 shares Directly owned shares reflecting prior option exercises and net RSU settlements

Key Terms

restricted stock units ("RSUs"), mandatory tax withholding, net settlement, contingent right

4 terms

restricted stock units ("RSUs") financial

"upon the non-reportable vesting and settlement of restricted stock units ("RSUs")."

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

mandatory tax withholding financial

"shares withheld by the Issuer to satisfy the mandatory tax withholding requirements"

net settlement financial

"reflects prior option exercises and the prior net settlement upon vesting of previously granted RSUs"

contingent right financial

"Each RSU represents a contingent right to receive one share of common stock"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did ADMA (ADMA) report for its COO?

Kaitlin M. Kestenberg-Messina had 3,177 ADMA shares withheld to cover taxes on vested RSUs. The shares, valued at $8.37 each, satisfied mandatory tax withholding and were explicitly described as not being an open-market sale of securities.

Was the ADMA (ADMA) insider transaction an open-market sale of shares?

No, the transaction was not an open-market sale of ADMA shares. The company states the 3,177 shares were withheld by the issuer solely to meet mandatory tax withholding obligations arising from the vesting and settlement of restricted stock units.

How many ADMA (ADMA) shares does the COO hold after this transaction?

After the tax-withholding disposition, the COO directly owned 443,061 ADMA common shares. This total reflects prior option exercises and past net RSU settlements, plus the impact of the 3,177 shares withheld to cover current RSU-related tax obligations.

What RSU awards related to this ADMA (ADMA) Form 4 are still unvested?

As of the transaction date, unvested awards included 91,631, 58,338, 96,160, 7,500, and 23,750 RSUs from grants between 2023 and 2026. Each RSU represents a contingent right to receive one ADMA common share upon vesting, subject to continued service.

What does transaction code "F" indicate in this ADMA (ADMA) insider report?

Transaction code F indicates payment of a tax liability by delivering or withholding securities. Here, it reflects ADMA withholding 3,177 common shares from the COO to satisfy mandatory RSU-related tax obligations rather than the executive selling shares in the market.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/28/2026 - 09:00 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kestenberg-Messina Kaitlin M.

(Last) (First) (Middle)

C/O ADMA BIOLOGICS, INC.

5800 PARK OF COMMERCE BLVD. NW

(Street)

BOCA RATON FLORIDA 33487

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ADMA BIOLOGICS, INC. [ ADMA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	COO and SVP, Compliance

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/24/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/24/2026		F		3,177(1)	D	$8.37	443,061(2)(3)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon the non-reportable vesting and settlement of restricted stock units ("RSUs"). This is not an open market sale of securities.

2. Includes, as of the transaction date, (i) 91,631 unvested RSUs out of 91,631 RSUs granted on February 9, 2026, vesting 25% on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (ii) 58,338 unvested RSUs out of 77,784 RSUs granted on February 19, 2025, vesting 25% on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (iii) 96,160 unvested RSUs out of 192,320 RSUs granted on April 1, 2024, vesting 25% on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;

3. (continued from footnote 2) (iv) 7,500 unvested RSUs out of 30,000 RSUs granted on July 24, 2023, vesting 25% on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (v) 23,750 unvested RSUs out of 95,000 RSUs granted on March 6, 2023, vesting 25% on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; and (vi) 165,682 shares of common stock directly owned by the Reporting Person, which reflects prior option exercises and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes. Each RSU represents a contingent right to receive one share of common stock of the Issuer.

	/s/ Kaitlin M. Kestenberg-Messina, by Michael A. Goldstein as Attorney-in-fact	07/28/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)